Updated October 2022

Are you interested in participating in a clinical trial?

Participating in a clinical trial can be a great way to get involved in thrombosis and cardiovascular research, but not every trial is right for every patient. Talk to your healthcare provider if you’re interested in learning more about eligibility for clinical trials. Learn more about what exactly happens in a clinical trial here.

Here are some opportunities available to patients:

  • C-TRACT Trial (Recruiting)
    The NIH-sponsored C-TRACT (Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy) study is designed to learn if endovascular therapy (EVT) procedures such as stent placement might reduce the severity of post-thrombotic syndrome (PTS) and improve quality of life. The C-TRACT researchers seek to enroll and follow 374 patients with moderate-to-severe PTS and blockage of the large veins draining the leg. All study participants will receive active treatment for their leg problem and will be monitored closely, and some patients will also be treated with the above EVT procedures.  To learn more, please visit the C-TRACT website. If you’re interested in participating, please contact the C-TRACT Clinical Trial Manager, Angela Oliver at 1-866-974-CLOT (2568) or [email protected].
  • PEPPER Trial (Recruiting)
    The PEPPER (Pulmonary Embolism Prevention after Hip & Knee Replacement) trial is investigating which blood thinner is best for preventing blood clots in patients who have total hip and knee replacement surgery. Researchers are currently looking to enroll 25,000 patients across 25 sites in North America. To learn more and to find out if the trial is recruiting near you, visit the PEPPER trial’s website. If you would like to participate, please contact the program manager, Carol Lambourne at 843-792-2913 or [email protected].
  • GUARD-AF Trial (Recruiting)
    The GUARD-AF (reducinG Stroke by Screening for UndiAgnosed atRial Fibrillation in Elderly inDividuals) trial will evaluate if detection of undiagnosed atrial fibrillation (Afib) in people age 70+ reduces stroke risk compared to usual care. Visit the GUARD-AF page at clinicaltrials.gov to learn more.